• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Estimation of population-based utility weights for gastric cancer-related health states.基于人群的胃癌相关健康状态效用权重估计。
Patient Prefer Adherence. 2018 May 23;12:909-918. doi: 10.2147/PPA.S151946. eCollection 2018.
2
Disease severity-based evaluation of utility weights for lung cancer-related health states in Korea.基于疾病严重程度的韩国肺癌相关健康状态效用权重评估。
BMC Cancer. 2018 Nov 8;18(1):1081. doi: 10.1186/s12885-018-4960-y.
3
Estimation of Utility Weights for Prostate-related Health States in Korea.韩国前列腺相关健康状况效用值的评估。
J Prev Med Public Health. 2022 May;55(3):243-252. doi: 10.3961/jpmph.21.426. Epub 2022 May 4.
4
Estimation of health state utilities in breast cancer.乳腺癌健康状态效用的评估。
Patient Prefer Adherence. 2017 Mar 14;11:531-536. doi: 10.2147/PPA.S129856. eCollection 2017.
5
Estimation of utility weights for major liver diseases according to disease severity in Korea.根据韩国主要肝脏疾病的严重程度估算效用权重
BMC Gastroenterol. 2017 Sep 5;17(1):103. doi: 10.1186/s12876-017-0660-3.
6
[Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].奥沙利铂联合S-1辅助化疗用于D2淋巴结清扫术后局部进展期胃癌患者的安全性和疗效
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Feb 25;24(2):145-152. doi: 10.3760/cma.j.cn.441530-20201016-00561.
7
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.胃切除术加化疗与单纯化疗治疗有单一不可治愈因素的晚期胃癌(REGATTA):一项 3 期随机对照试验。
Lancet Oncol. 2016 Mar;17(3):309-318. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26.
8
Estimation of population-based utility weights for health states of chronic kidney disease, dialysis and kidney transplantation.估算慢性肾脏病、透析和肾移植健康状况的基于人群的效用权重。
Nephrology (Carlton). 2020 Jul;25(7):544-550. doi: 10.1111/nep.13700. Epub 2020 Feb 12.
9
Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in Korea.估算韩国结直肠癌相关健康状况的效用权重和质量调整生命年损失。
Sci Rep. 2017 Jul 17;7(1):5571. doi: 10.1038/s41598-017-06004-6.
10
Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.2011年中国国家综合癌症网络(NCCN)《肿瘤临床实践指南:胃癌》中新增的可切除胃癌患者辅助化疗的成本效用分析
Pharmacoeconomics. 2014 Mar;32(3):235-43. doi: 10.1007/s40273-013-0065-2.

引用本文的文献

1
The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study.在韩国国家胃癌筛查项目中增加幽门螺杆菌筛查的成本效益:成本效益建模研究方案
JMIR Res Protoc. 2025 Jul 15;14:e72228. doi: 10.2196/72228.
2
Cost Utility Analysis of National Cancer Screening Program for Gastric Cancer in Korea: A Markov Model Analysis.韩国国家胃癌筛查项目的成本效用分析:马尔可夫模型分析
J Korean Med Sci. 2025 Feb 17;40(6):e43. doi: 10.3346/jkms.2025.40.e43.
3
Utility Values of Health Status in Gastric Cancer: A Systematic Review.胃癌健康状况的效用值:一项系统评价
Value Health Reg Issues. 2025 Mar;46:101063. doi: 10.1016/j.vhri.2024.101063. Epub 2025 Feb 1.
4
Cost-Effectiveness of Serum Pepsinogen as a Gastric Cancer Targeted Screening Strategy in the United States.血清胃蛋白酶原作为美国胃癌靶向筛查策略的成本效益
Gastro Hep Adv. 2024 Oct 10;4(2):100564. doi: 10.1016/j.gastha.2024.10.004. eCollection 2025.
5
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.加拿大安大略省多癌种早期检测血液检测与标准护理筛查的成本效益探索性分析。
Pharmacoeconomics. 2024 Apr;42(4):393-407. doi: 10.1007/s40273-023-01345-9. Epub 2023 Dec 27.
6
Cost-effectiveness analysis of the artificial intelligence diagnosis support system for early gastric cancers.早期胃癌人工智能诊断支持系统的成本效益分析
DEN Open. 2023 Aug 28;4(1):e289. doi: 10.1002/deo2.289. eCollection 2024 Apr.
7
A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.基于人群的幽门螺杆菌根除策略比内镜筛查更具成本效益。
Dig Dis Sci. 2023 May;68(5):1735-1746. doi: 10.1007/s10620-022-07795-z. Epub 2022 Dec 24.
8
Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.在日本国家胃癌政策中引入幽门螺杆菌根除策略的经济和健康影响:成本效益分析。
Helicobacter. 2021 Oct;26(5):e12837. doi: 10.1111/hel.12837. Epub 2021 Jul 18.
9
Elicitation of Health Utilities in Oncology in the Kingdom of Saudi Arabia.沙特阿拉伯王国肿瘤学领域健康效用的获取
JCO Glob Oncol. 2020 Oct;6:1609-1616. doi: 10.1200/GO.20.00234.
10
A decision analysis comparing three strategies for peritoneal lavage cytology testing in staging of gastric cancer in China.在中国胃癌分期中比较三种腹膜灌洗细胞学检测策略的决策分析。
Cancer Med. 2020 Dec;9(23):8940-8949. doi: 10.1002/cam4.3518. Epub 2020 Oct 13.

本文引用的文献

1
Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in Korea.估算韩国结直肠癌相关健康状况的效用权重和质量调整生命年损失。
Sci Rep. 2017 Jul 17;7(1):5571. doi: 10.1038/s41598-017-06004-6.
2
The EQ-5D-5L is More Discriminative Than the EQ-5D-3L in Patients with Diabetes in Singapore.在新加坡糖尿病患者中,EQ-5D-5L比EQ-5D-3L更具区分能力。
Value Health Reg Issues. 2016 May;9:57-62. doi: 10.1016/j.vhri.2015.11.003. Epub 2016 Jan 19.
3
Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.晚期胃癌二线化疗药物的成本效益分析
Pharmacotherapy. 2017 Jan;37(1):94-103. doi: 10.1002/phar.1870. Epub 2017 Jan 6.
4
Economic burden of gastrointestinal cancer under the protection of the New Rural Cooperative Medical Scheme in a region of rural China with high incidence of oesophageal cancer: cross-sectional survey.中国农村食管癌高发地区新型农村合作医疗制度保障下胃肠道癌症的经济负担:横断面调查
Trop Med Int Health. 2016 Jul;21(7):907-16. doi: 10.1111/tmi.12715. Epub 2016 May 25.
5
Systematic review on quality of life outcomes after gastrectomy for gastric carcinoma.胃癌胃切除术后生活质量结局的系统评价
J Gastrointest Oncol. 2015 Oct;6(5):544-60. doi: 10.3978/j.issn.2078-6891.2015.046.
6
Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review.与晚期胃癌、食管癌或胃食管交界腺癌相关的健康状态效用值:一项系统评价。
J Med Econ. 2015;18(11):954-66. doi: 10.3111/13696998.2015.1066380. Epub 2015 Sep 11.
7
The Global Burden of Cancer 2013.《2013 年全球癌症负担》。
JAMA Oncol. 2015 Jul;1(4):505-27. doi: 10.1001/jamaoncol.2015.0735.
8
Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy?食管胃交界腺癌手术后的长期生活质量:扩大胃切除术还是经胸食管切除术?
Gastric Cancer. 2016 Jan;19(1):312-7. doi: 10.1007/s10120-015-0466-3. Epub 2015 Jan 28.
9
Health-related quality of life and utilities in gastric premalignant conditions and malignant lesions: a multicentre study in a high prevalence country.胃癌前病变和恶性病变中与健康相关的生活质量及效用:在一个高发病率国家开展的多中心研究
J Gastrointestin Liver Dis. 2014 Dec;23(4):371-8. doi: 10.15403/jgld.2014.1121.234.hrq.
10
Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.D2胃切除术后胃癌患者辅助化疗的成本效益分析
BMC Cancer. 2014 Dec 19;14:984. doi: 10.1186/1471-2407-14-984.

基于人群的胃癌相关健康状态效用权重估计。

Estimation of population-based utility weights for gastric cancer-related health states.

作者信息

Lee Hyeon-Jeong, Ock Minsu, Kim Kyu-Pyo, Jo Min-Woo

机构信息

Department of Preventive Medicine, University of Ulsan College of Medicine, Seoul, Korea.

Department of Preventive Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.

出版信息

Patient Prefer Adherence. 2018 May 23;12:909-918. doi: 10.2147/PPA.S151946. eCollection 2018.

DOI:10.2147/PPA.S151946
PMID:29872276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5973464/
Abstract

BACKGROUND

This study aimed to generate utility weights of gastric cancer-related health states from the perspective of the Korean general population.

METHODS

The Korean adults (age ≥19 years) included in the study were sampled using multistage quota sampling methods stratified by sex, age, and education level. Nine scenarios for hypothetical gastric cancer-related health states were developed and reviewed. After consenting to participate, the subjects were surveyed by trained interviewers using a computer-assisted personal interview method. Participants were asked to perform standard gamble tasks to measure the utility weights of 5 randomly assigned health states (from among nine scenarios). The mean utility weight was calculated for each health state.

RESULTS

Three hundred twenty-six of the 407 adults who completed this study were included in the analysis. The mean utility weights from the standard gamble were 0.857 (no gastric cancer with infection), 0.773 (early gastric cancer [EGC] with endoscopic surgery), 0.779 (EGC with subtotal gastrectomy), 0.767 (EGC with total gastrectomy), 0.602 (advanced gastric cancer with subtotal gastrectomy and adjuvant chemotherapy), 0.643 (advanced gastric cancer with total gastrectomy and adjuvant chemotherapy), 0.522 (advanced gastric cancer with extended gastrectomy and adjuvant chemotherapy), 0.404 (metastatic gastric cancer with palliative chemotherapy), and 0.399 (recurrent gastric cancer with palliative chemotherapy).

CONCLUSION

This study was the first to comprehensively estimate the utility weights of gastric cancer-related health states in a general population. The utility weights derived from this study could be useful for future economic evaluations related to gastric cancer interventions.

摘要

背景

本研究旨在从韩国普通人群的角度生成胃癌相关健康状态的效用权重。

方法

采用按性别、年龄和教育水平分层的多阶段配额抽样方法,对纳入研究的韩国成年人(年龄≥19岁)进行抽样。制定并审查了9种假设的胃癌相关健康状态情景。在同意参与后,由经过培训的访谈员使用计算机辅助个人访谈方法对受试者进行调查。参与者被要求执行标准博弈任务,以测量5个随机分配的健康状态(来自9种情景)的效用权重。计算每种健康状态的平均效用权重。

结果

完成本研究的407名成年人中,有326人纳入分析。标准博弈得出的平均效用权重分别为:0.857(无胃癌伴感染)、0.773(早期胃癌[EGC]行内镜手术)、0.779(EGC行胃次全切除术)、0.767(EGC行全胃切除术)、0.602(进展期胃癌行胃次全切除术及辅助化疗)、0.643(进展期胃癌行全胃切除术及辅助化疗)、0.522(进展期胃癌行扩大胃切除术及辅助化疗)、0.404(转移性胃癌行姑息化疗)和0.399(复发性胃癌行姑息化疗)。

结论

本研究首次全面估计了普通人群中胃癌相关健康状态的效用权重。本研究得出的效用权重可能有助于未来与胃癌干预措施相关的经济评估。